vs
Protalix BioTherapeutics, Inc.（PLX）与VALUE LINE INC（VALU）财务数据对比。点击上方公司名可切换其他公司
Protalix BioTherapeutics, Inc.的季度营收约是VALUE LINE INC的1.1倍（$9.1M vs $8.3M），VALUE LINE INC净利率更高（71.4% vs -60.3%，领先131.7%），VALUE LINE INC同比增速更快（-7.7% vs -49.9%），过去两年VALUE LINE INC的营收复合增速更高（-4.1% vs -6.7%）
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
价值线公司是一家总部位于纽约的上市投资研究与金融出版企业，由阿诺德·伯恩哈德于1931年创立。该公司最为人熟知的业务是出版《价值线投资调查》，这份股票分析刊物跟踪覆盖约1700只上市个股的行情与研究。
PLX vs VALU — 直观对比
营收规模更大
PLX
是对方的1.1倍
$8.3M
营收增速更快
VALU
高出42.2%
-49.9%
净利率更高
VALU
高出131.7%
-60.3%
两年增速更快
VALU
近两年复合增速
-6.7%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $9.1M | $8.3M |
| 净利润 | $-5.5M | $5.9M |
| 毛利率 | 49.4% | — |
| 营业利润率 | -51.1% | 12.1% |
| 净利率 | -60.3% | 71.4% |
| 营收同比 | -49.9% | -7.7% |
| 净利润同比 | -184.8% | 14.5% |
| 每股收益（稀释后） | $-0.06 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PLXVALU
| Q1 26 | — | $8.3M | ||
| Q4 25 | $9.1M | $8.6M | ||
| Q3 25 | $17.9M | $8.6M | ||
| Q2 25 | $15.7M | $8.4M | ||
| Q1 25 | $10.1M | $9.0M | ||
| Q4 24 | $18.2M | $8.8M | ||
| Q3 24 | $18.0M | $8.9M | ||
| Q2 24 | $13.5M | $9.0M |
净利润PLXVALU
| Q1 26 | — | $5.9M | ||
| Q4 25 | $-5.5M | $5.7M | ||
| Q3 25 | $2.4M | $6.5M | ||
| Q2 25 | $164.0K | $4.0M | ||
| Q1 25 | $-3.6M | $5.2M | ||
| Q4 24 | $6.5M | $5.7M | ||
| Q3 24 | $3.2M | $5.9M | ||
| Q2 24 | $-2.2M | $4.8M |
毛利率PLXVALU
| Q1 26 | — | — | ||
| Q4 25 | 49.4% | — | ||
| Q3 25 | 53.4% | — | ||
| Q2 25 | 62.5% | — | ||
| Q1 25 | 19.1% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 53.4% | — | ||
| Q2 24 | 29.8% | — |
营业利润率PLXVALU
| Q1 26 | — | 12.1% | ||
| Q4 25 | -51.1% | 17.7% | ||
| Q3 25 | 11.9% | 17.4% | ||
| Q2 25 | 7.5% | 9.9% | ||
| Q1 25 | -41.0% | 17.4% | ||
| Q4 24 | 39.6% | 19.7% | ||
| Q3 24 | 22.2% | 20.8% | ||
| Q2 24 | -18.0% | 16.5% |
净利率PLXVALU
| Q1 26 | — | 71.4% | ||
| Q4 25 | -60.3% | 66.4% | ||
| Q3 25 | 13.2% | 75.1% | ||
| Q2 25 | 1.0% | 47.1% | ||
| Q1 25 | -35.8% | 57.6% | ||
| Q4 24 | 35.6% | 64.3% | ||
| Q3 24 | 18.0% | 66.3% | ||
| Q2 24 | -16.4% | 53.1% |
每股收益（稀释后）PLXVALU
| Q1 26 | — | — | ||
| Q4 25 | $-0.06 | — | ||
| Q3 25 | $0.03 | — | ||
| Q2 25 | $0.00 | — | ||
| Q1 25 | $-0.05 | — | ||
| Q4 24 | $0.10 | — | ||
| Q3 24 | $0.03 | — | ||
| Q2 24 | $-0.03 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $14.7M | $92.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $48.2M | $107.8M |
| 总资产 | $82.3M | $151.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PLXVALU
| Q1 26 | — | $92.5M | ||
| Q4 25 | $14.7M | $86.6M | ||
| Q3 25 | $13.6M | $33.7M | ||
| Q2 25 | $17.9M | $67.7M | ||
| Q1 25 | $19.5M | $52.8M | ||
| Q4 24 | $19.8M | $22.3M | ||
| Q3 24 | $27.4M | $30.9M | ||
| Q2 24 | $23.4M | $4.4M |
股东权益PLXVALU
| Q1 26 | — | $107.8M | ||
| Q4 25 | $48.2M | $105.5M | ||
| Q3 25 | $52.9M | $103.0M | ||
| Q2 25 | $49.9M | $99.7M | ||
| Q1 25 | $45.2M | $99.0M | ||
| Q4 24 | $43.2M | $96.7M | ||
| Q3 24 | $32.4M | $93.9M | ||
| Q2 24 | $28.6M | $90.8M |
总资产PLXVALU
| Q1 26 | — | $151.0M | ||
| Q4 25 | $82.3M | $147.9M | ||
| Q3 25 | $82.3M | $148.2M | ||
| Q2 25 | $78.5M | $144.5M | ||
| Q1 25 | $73.9M | $143.6M | ||
| Q4 24 | $73.4M | $140.0M | ||
| Q3 24 | $61.6M | $138.6M | ||
| Q2 24 | $91.5M | $136.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.0M | $5.3M |
| 自由现金流经营现金流 - 资本支出 | $1.6M | — |
| 自由现金流率自由现金流/营收 | 17.8% | — |
| 资本支出强度资本支出/营收 | 4.4% | 0.0% |
| 现金转化率经营现金流/净利润 | — | 0.89× |
| 过去12个月自由现金流最近4个季度 | $-13.6M | — |
8季度趋势，按日历期对齐
经营现金流PLXVALU
| Q1 26 | — | $5.3M | ||
| Q4 25 | $2.0M | $3.0M | ||
| Q3 25 | $-3.7M | $5.6M | ||
| Q2 25 | $-5.2M | $20.2M | ||
| Q1 25 | $-5.1M | $6.9M | ||
| Q4 24 | $4.0M | $3.1M | ||
| Q3 24 | $4.1M | $4.8M | ||
| Q2 24 | $-3.6M | $17.9M |
自由现金流PLXVALU
| Q1 26 | — | — | ||
| Q4 25 | $1.6M | — | ||
| Q3 25 | $-4.2M | — | ||
| Q2 25 | $-5.7M | $20.1M | ||
| Q1 25 | $-5.4M | $6.8M | ||
| Q4 24 | $3.6M | $3.0M | ||
| Q3 24 | $4.0M | $4.8M | ||
| Q2 24 | $-3.8M | $17.9M |
自由现金流率PLXVALU
| Q1 26 | — | — | ||
| Q4 25 | 17.8% | — | ||
| Q3 25 | -23.7% | — | ||
| Q2 25 | -36.2% | 239.2% | ||
| Q1 25 | -53.0% | 75.3% | ||
| Q4 24 | 19.6% | 34.1% | ||
| Q3 24 | 22.4% | 53.7% | ||
| Q2 24 | -28.1% | 199.0% |
资本支出强度PLXVALU
| Q1 26 | — | 0.0% | ||
| Q4 25 | 4.4% | 0.0% | ||
| Q3 25 | 2.8% | 0.0% | ||
| Q2 25 | 2.8% | 2.1% | ||
| Q1 25 | 3.0% | 1.2% | ||
| Q4 24 | 2.3% | 0.7% | ||
| Q3 24 | 0.5% | 0.0% | ||
| Q2 24 | 1.3% | 0.2% |
现金转化率PLXVALU
| Q1 26 | — | 0.89× | ||
| Q4 25 | — | 0.52× | ||
| Q3 25 | -1.58× | 0.86× | ||
| Q2 25 | -31.91× | 5.12× | ||
| Q1 25 | — | 1.33× | ||
| Q4 24 | 0.61× | 0.54× | ||
| Q3 24 | 1.27× | 0.81× | ||
| Q2 24 | — | 3.75× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
VALU
暂无分部数据
